Two large, phase III trials (A011502, “Aspirin in Preventing Recurrence of Cancer in Patients with HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy;” and A011401, “Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer”) completed enrollment and closed to further accrual on December 7, 2020 and February 15, 2021, respectively. Here, ERBB2 is linked to cancer.